Contact us Demo our platform

Metabolon @

Neuroscience 2023

Metabolon is thrilled to participate as an exhibitor at the highly anticipated Neuroscience 2023 conference hosted by the Society for Neuroscience (SFN). The event, renowned for its focus on advancing scientific understanding in the field of neuroscience, will take place at the Walter E. Washington Convention Center from November 11-15, 2023.

Booth No. 2402 – View Map

Poster Presentation

Identifying Changes in Phytocannabinoid and Endocannabinoid Metabolites in Cannabis Users Utilizing a Novel UPLC-MS/MS Panel

Date: November 11, 2023, 1:00 PM – 5:00 PM
Session: PSTR046 – Cannabinoids: Behavioral and Neural Mechanisms and Addiction
Poster No. PSTR046.08
Location: WCC Halls A-C
Presenter: Dr. Scott Hutton

Abstract:
Cannabinoid signaling plays a crucial role in the regulation of diverse neurological processes. However, the complex interactions between exogenous and endogenous cannabinoids in the human body remain unclear. The endogenous endocannabinoid system (ECS) modulates a broad spectrum of neurological functions, including pain perception, appetite, mood, memory, motor function, and inflammatory responses. Moreover, dysregulation of the ECS has been implicated in the pathogenesis of many disorders such as chronic pain, inflammatory disease, neurological disorders, and cancer. Exogenous phytocannabinoids are a diverse group of bioactive compounds found in Cannabis sativa that have been shown to act as exogenous ligands for the ECS, exerting diverse physiological effects on ECS-regulated pathways. As a result, there is significant interest in exploring the potential therapeutic applications of these compounds for ECS-modulated ailments. However, quantifying cannabinoids and their metabolites present unique challenges due to their low abundance and structural variability. A novel targeted UPLC-MS/MS method based metabolomic panel was developed to investigate the potential relationship between cannabis use and endocannabinoid levels in plasma samples from consenting young adults (age 18-25) diagnosed with cannabis use disorder (CUD) based on DSM-5 criteria. Our analysis measured up to eleven endocannabinoids, fifteen phytocannabinoids, and their associated metabolites. Statistically significant differences were observed between the CUD samples and the control group. As expected, tetrahydrocannabinols including delta 9-THC, delta 8-THC, and CBN, as well as human metabolites 11-COOH-THC and 11-OH-THC, were significantly elevated in the CUD group compared to the control group. Conversely, multiple neurotransmitter-conjugated acyl amide endocannabinoid metabolites were significantly reduced in individuals with CUD. Interestingly, these acyl amides are synthesized by the enzyme fatty acid amide hydrolase (FAAH), which previous studies have shown to be differentially expressed in young adult cannabis users. Therefore, the use of our cannabinoid targeted metabolomics panel reveals for the first time an indirect correlation between plasma levels of phytocannabinoid metabolites and neurotransmitter-conjugated acyl amide endocannabinoids in individuals with CUD. Moreover, our study supports the use of targeted metabolomics in providing novel insight involving phyto- and endocannabinoid signaling.

Link to Poster Details: Identifying changes in phytocannabinoid and endocannabinoid metabolites in cannabis users utilizing a novel UPLC-MS/MS panel (abstractsonline.com)

Schedule a Meeting

Latest Resources

Access a wealth of valuable resources to deepen your understanding about metabolomics and the scientific advancements it has empowered.

✕

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.